Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


Background: Subcutaneous immunoglobulin (SCIG) is effective treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Quality of life (QoL) increases following switch from intravenous administration to SCIG, but its correlation with clinical functioning is sparsely studied.

Aims of the study: The aim of this study is to evaluate the correlation between QoL and clinical functioning in CIDP patients treated with SCIG.

Methods: Danish patients with CIDP with a disease duration

Results: Of 92 eligible patients, 44 were included. QoL on the visual analogue scale (VAS) was 65% (range: 15-90) of the level of healthy controls (P = .03) and correlated to impaired gait function by 40-MWT and 6-SST. QoL correlated to RODS and ODSS, whereas there was no correlation with the MRC score.

Conclusions: In SCIG treated CIDP patients QoL is reduced and correlates to gait performance and disability.

BogserieActa Neurologica Scandinavica. Supplementum
Sider (fra-til)637-640
Antal sider4
StatusUdgivet - dec. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 195425232